InnoCan Pharma (IP40) Stock Overview
Operates as a pharmaceutical technology company in United States, Canada, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
IP40 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
InnoCan Pharma Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.38 |
| 52 Week High | CA$13.20 |
| 52 Week Low | CA$1.28 |
| Beta | -0.26 |
| 1 Month Change | 1.48% |
| 3 Month Change | -34.21% |
| 1 Year Change | -82.43% |
| 3 Year Change | -91.20% |
| 5 Year Change | -97.48% |
| Change since IPO | -29.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| IP40 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -8.3% | -2.7% | -0.5% |
| 1Y | -82.4% | 40.5% | 4.6% |
Return vs Industry: IP40 underperformed the German Pharmaceuticals industry which returned 40.8% over the past year.
Return vs Market: IP40 underperformed the German Market which returned 5.5% over the past year.
Price Volatility
| IP40 volatility | |
|---|---|
| IP40 Average Weekly Movement | 16.1% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 12.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: IP40's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: IP40's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Iris Bincovich | innocanpharma.com |
InnoCan Pharma Corporation operates as a pharmaceutical technology company in United States, Canada, Europe, and internationally. The company operates through two segments, Online sales and Other Operations. The company develops a cannabidiol (CBD)-loaded liposome drug delivery platform (CBD-LPT), which is in the preclinical trial phase to treat chronic pain management for human and veterinary health sectors.
InnoCan Pharma Corporation Fundamentals Summary
| IP40 fundamental statistics | |
|---|---|
| Market cap | €6.58m |
| Earnings (TTM) | -€824.55k |
| Revenue (TTM) | €20.23m |
Is IP40 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IP40 income statement (TTM) | |
|---|---|
| Revenue | US$23.53m |
| Cost of Revenue | US$2.25m |
| Gross Profit | US$21.28m |
| Other Expenses | US$22.24m |
| Earnings | -US$959.00k |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 90.46% |
| Net Profit Margin | -4.08% |
| Debt/Equity Ratio | 22.5% |
How did IP40 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/09 16:55 |
| End of Day Share Price | 2026/09/09 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
InnoCan Pharma Corporation is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.